| Zinzani, Pier Luigi |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 06/25 | 01/28 | | |
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients |
|
|
| Recruiting | 3 | 120 | Europe | Rituximab, Truxima, Zanubrutinib, Brukinsa | International Extranodal Lymphoma Study Group (IELSG) | Splenic Marginal Zone Lymphoma | 05/29 | 05/29 | | |
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2/3 | 501 | Europe, US, RoW | Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Relapsed/refractory Diffuse Large B-cell Lymphoma | 12/24 | 12/25 | | |
| Active, not recruiting | 2 | 170 | Europe, US | IPH4102, lacutamab | Innate Pharma | Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome | 10/23 | 01/26 | | |
|
|
|
|
|
|
| Active, not recruiting | 2 | 82 | Europe, US, RoW | brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone | Seagen Inc. | Peripheral T-cell Lymphoma | 05/24 | 12/25 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Not yet recruiting | 2 | 56 | Europe | Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 09/28 | 09/33 | | |
| Active, not recruiting | 2 | 28 | Europe | Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet | Niguarda Hospital | CLL Transformation | 09/26 | 12/26 | | |
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy |
|
|
| Recruiting | 2 | 28 | Europe | Tislelizumab | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/27 | 11/29 | | |
| Recruiting | 1/2 | 60 | Europe, US | EO2463, lenalidomide, Revlimid, rituximab, MabThera | Enterome | Follicular Lymphoma, Marginal Zone Lymphoma | 05/26 | 05/32 | | |
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) |
|
|
| Recruiting | 1/2 | 160 | Europe, Canada, US, RoW | ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide | Allogene Therapeutics | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | 01/25 | 05/29 | | |
| Recruiting | 1/2 | 210 | Europe, US, RoW | CPI-0209 | Constellation Pharmaceuticals | Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma | 12/25 | 03/26 | | |
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
|
|
| Completed | 1 | 106 | Europe, US | Tinostamustine, EDO-S101 | Mundipharma Research Limited | Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma | 05/23 | 11/23 | | |
POSS, NCT06734078: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme |
|
|
| Active, not recruiting | N/A | 100 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | DLBCL - Diffuse Large B Cell Lymphoma | 12/25 | 12/25 | | |
| Recruiting | N/A | 1300 | Europe | COVID-19 vaccines | Azienda Unità Sanitaria Locale Reggio Emilia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Clinico Humanitas, IRCCS San Raffaele, Regina Elena Cancer Institute, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS, University of Roma La Sapienza, Fondazione IRCCS Policlinico San Matteo di Pavia, Istituti Fisioterapici Ospitalieri, Istituto Tumori Giovanni Paolo II, BARI, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna | COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder, Rheumatic Diseases | 07/21 | 04/22 | | |
| Recruiting | N/A | 1500 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Lymphoma | 08/26 | 08/26 | | |
| Recruiting | N/A | 5500 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Lymphoproliferative Syndrome, Autoimmune, Lymphoma | 12/27 | 12/27 | | |
PRIMICI, NCT06781450: Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life Context |
|
|
| Recruiting | N/A | 50 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Primary Mediastinal B Cell Lymphoma | 12/25 | 12/25 | | |
PIXBRIDGE, NCT06760936: Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients |
|
|
| Active, not recruiting | N/A | 15 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Diffuse Large B Cell Lymphoma (DLBCL) | 12/25 | 12/25 | | |
MEPI-AGE, NCT06761274: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 200 | Europe | peripheral blood sampling | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Hodgkin Lymphoma in Remission | 09/25 | 09/25 | | |
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context |
|
|
| Recruiting | N/A | 65 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Castleman Disease | 01/25 | 01/25 | | |
AMICO, NCT06814405: Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management with Early Discharge of Patients with Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital |
|
|
| Recruiting | N/A | 100 | Europe | Home patient management, Hospital patient management | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Haematological Malignancy | 12/25 | 12/25 | | |
NCT03797170: Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma |
|
|
| Active, not recruiting | N/A | 50 | Europe | Gut microbiota samples | University of Bologna | Diffuse Large B Cell Lymphoma | 07/23 | 12/23 | | |
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) |
|
|
| Recruiting | N/A | 200 | Europe | | Incyte Biosciences Italy S.r.l, Advice Pharma Group srl | DLBCL - Diffuse Large B Cell Lymphoma | 06/25 | 06/27 | | |
LNH012, NCT06026644: Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life |
|
|
| Active, not recruiting | N/A | 170 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | DLBCL - Diffuse Large B Cell Lymphoma | 02/24 | 04/26 | | |
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. |
|
|
| Not yet recruiting | N/A | 125 | Europe | Zanubrutinib | Fondazione Italiana Linfomi - ETS | Waldenström's Macroglobulinemia (WM) | 07/26 | 07/26 | | |
HL-SIP, NCT06733987: Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 40 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Hodgkin Lymphoma | 02/27 | 02/27 | | |
CLIO, NCT06720701: Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma. |
|
|
| Not yet recruiting | N/A | 125 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Non-Hodgkin Lymphoma | 12/26 | 12/26 | | |
| Not yet recruiting | N/A | 400 | Europe | | Fondazione Italiana Linfomi - ETS, Takeda | Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome | 07/26 | 07/26 | | |
| Recruiting | N/A | 45 | Europe | Peripheral and BM blood sample | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Hairy Cell Leukemia | 11/25 | 11/25 | | |
| Recruiting | N/A | 150 | Europe | | Fondazione Italiana Linfomi - ETS | Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome | 05/25 | 07/25 | | |
| Recruiting | N/A | 160 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Marginal Zone B Cell Lymphoma | 10/25 | 10/25 | | |
| Recruiting | N/A | 1000 | US | | University of Pennsylvania, EUSA Pharma, Inc., Castleman Disease Collaborative Network, Food and Drug Administration (FDA) | Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant | 09/26 | 09/26 | | |
MicroCar, NCT05725720: Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy |
|
|
| Recruiting | N/A | 90 | Europe | Gut microbiome analysis | University of Bologna, Associazione Italiana per la Ricerca sul Cancro, IRCCS Azienda Ospedaliero-Universitaria di Bologna | Diffuse Large B Cell Lymphoma | 07/27 | 12/27 | | |
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma |
|
|
| Recruiting | N/A | 300 | Europe, US, RoW | | International Extranodal Lymphoma Study Group (IELSG) | Nodal Marginal Zone Lymphoma | 12/26 | 12/26 | | |
| Re, Alessandro |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
|
| Recruiting | 2 | 28 | Europe | Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | Plasmablastic Lymphoma | 01/25 | 01/25 | | |
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
|
|
| Recruiting | 2 | 49 | Europe | Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C) | Fondazione Italiana Linfomi - ETS | Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 04/26 | 04/29 | | |
| Recruiting | 1/2 | 122 | Europe | Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Relapsed or Refractory Hodgkin's Lymphoma | 04/27 | 04/30 | | |
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication |
|
|
| Active, not recruiting | N/A | 200 | Europe | | Fondazione Italiana Linfomi - ETS | Mantle Cell Lymphoma | 10/23 | 01/25 | | |
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. |
|
|
| Recruiting | N/A | 80 | Europe | | Fondazione Italiana Linfomi - ETS | Mantle Cell Lymphoma | 03/25 | 03/25 | | |
| Not yet recruiting | N/A | 200 | Europe | | Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia | Plasmablastic Lymphoma | 02/28 | 02/28 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
| Nassi, Luca |
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi |
|
|
| Recruiting | 3 | 190 | Europe | Radiotherapy, Radiotherapy plus Obinutuzumab | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Follicular Lymphoma | 04/31 | 04/31 | | |
| Completed | 2 | 72 | Europe | Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide | International Extranodal Lymphoma Study Group (IELSG) | Primary Central Nervous System Lymphoma | 12/24 | 12/24 | | |
| Recruiting | 2 | 28 | Europe | Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | Plasmablastic Lymphoma | 01/25 | 01/25 | | |
| Not yet recruiting | 2 | 56 | Europe | Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 09/28 | 09/33 | | |
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
|
|
| Recruiting | 2 | 49 | Europe | Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C) | Fondazione Italiana Linfomi - ETS | Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 04/26 | 04/29 | | |
| Recruiting | 2 | 244 | Europe, Canada, US, RoW | Selinexor, KPT-330 | Karyopharm Therapeutics Inc | Diffuse Large B-cell Lymphoma | 04/27 | 11/27 | | |
|
|
|
|
|
|
|
|
|
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Withdrawn | 2 | 150 | Europe | R-DHAP, Pola-R-DHAP | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | 01/29 | 01/29 | | |
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context |
|
|
| Recruiting | N/A | 65 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Castleman Disease | 01/25 | 01/25 | | |
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. |
|
|
| Recruiting | N/A | 80 | Europe | | Fondazione Italiana Linfomi - ETS | Mantle Cell Lymphoma | 03/25 | 03/25 | | |
| Not yet recruiting | N/A | 200 | Europe | | Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia | Plasmablastic Lymphoma | 02/28 | 02/28 | | |
| Recruiting | N/A | 150 | Europe | | Fondazione Italiana Linfomi - ETS | Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome | 05/25 | 07/25 | | |
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis |
|
|
| Recruiting | N/A | 400 | Europe | Treatment for clinical practise | Fondazione Italiana Linfomi ONLUS | Classical Hodgkin Lymphoma | 01/26 | 01/26 | | |
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors |
|
|
| Recruiting | N/A | 552 | Europe | Lifestyles Implemented-Survivorship Care Plan (LS-SCP) | Fondazione Italiana Linfomi - ETS | Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | 02/26 | 02/26 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
| Puccini, Benedetta |
| Active, not recruiting | 3 | 128 | Europe | R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R) | Fondazione Italiana Linfomi - ETS | Lymphoma, Follicular | 01/23 | 08/27 | | |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
| Recruiting | 3 | 430 | Europe | Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses | Fondazione Italiana Linfomi ONLUS, GRADE Onlus | Diffuse Large B-Cell Lymphoma, Elderly Patients | 09/25 | 09/30 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
| Completed | 2 | 72 | Europe | Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide | International Extranodal Lymphoma Study Group (IELSG) | Primary Central Nervous System Lymphoma | 12/24 | 12/24 | | |
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication |
|
|
| Active, not recruiting | N/A | 200 | Europe | | Fondazione Italiana Linfomi - ETS | Mantle Cell Lymphoma | 10/23 | 01/25 | | |
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project |
|
|
| Recruiting | N/A | 130 | Europe | Chimeric Antigen Receptor T-cells (CAR-T) therapy | Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company | Non-hodgkin Lymphoma,B Cell | 07/26 | 07/26 | | |
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial |
|
|
| Recruiting | N/A | 654 | Europe | EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 06/25 | 06/26 | | |
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. |
|
|
| Not yet recruiting | N/A | 125 | Europe | Zanubrutinib | Fondazione Italiana Linfomi - ETS | Waldenström's Macroglobulinemia (WM) | 07/26 | 07/26 | | |
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 150 | Europe | | Fondazione Italiana Linfomi - ETS | Low Grade Non-Hodgkin's Lymphoma, Adult | 02/25 | 02/25 | | |
| Minoia, Carla |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients |
|
|
| Recruiting | 3 | 120 | Europe | Rituximab, Truxima, Zanubrutinib, Brukinsa | International Extranodal Lymphoma Study Group (IELSG) | Splenic Marginal Zone Lymphoma | 05/29 | 05/29 | | |
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi |
|
|
| Recruiting | 3 | 190 | Europe | Radiotherapy, Radiotherapy plus Obinutuzumab | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Follicular Lymphoma | 04/31 | 04/31 | | |
| Recruiting | N/A | 350 | Europe | | International Extranodal Lymphoma Study Group (IELSG) | Marginal Zone Lymphoma | 12/25 | 12/25 | | |
| Recruiting | N/A | 190 | Europe | acalabrutinib, Calquence | AstraZeneca, Yghea | Chronic Lymphocytic Leukemia | 02/30 | 02/30 | | |
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 150 | Europe | | Fondazione Italiana Linfomi - ETS | Low Grade Non-Hodgkin's Lymphoma, Adult | 02/25 | 02/25 | | |
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors |
|
|
| Recruiting | N/A | 552 | Europe | Lifestyles Implemented-Survivorship Care Plan (LS-SCP) | Fondazione Italiana Linfomi - ETS | Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | 02/26 | 02/26 | | |
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma |
|
|
| Recruiting | N/A | 300 | Europe, US, RoW | | International Extranodal Lymphoma Study Group (IELSG) | Nodal Marginal Zone Lymphoma | 12/26 | 12/26 | | |
